ALTHX — Theranexus SA Share Price
0.000.00%
Last trade - 00:00- €4.92m
- €3.66m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.21 | ||
| Price to Tang. Book | 4.6 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -129.8% | ||
| Return on Equity | -171.78% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Theranexus SA is a France-based company engaged in the healthcare industry. The Company is a biopharmaceutical entity that develops drug candidates to be used in the treatment of central nervous system (CNS) disorders, including epilepsy, narcolepsy, Parkinson's disease, Alzheimer's disease, neuropathic pain and psychiatric disorders. Its patented technology is aimed at increasing the efficacy of CNS drugs, which are approved and available on the market. The Company's technology is protected, scalable and versatile, and used to generate high value-added proprietary drug candidates for different conditions, while reducing time-to-market and market entry costs and risks in comparison with standard drug development processes. Theranexus SA operates in the domestic market.
Directors
- Franck Mouthon CHM
- Mathieu Charveriat DCE
- Thierry Lambert CFO (65)
- Werner Rein OTH
- Julien Veys OTH
- Sebastien Descarpentries DRC
- Rodolphe Besserve IND
- Eric Doulat IND
- Jerome Martinez IND (51)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 2nd, 2013
- Public Since
- October 30th, 2017
- No. of Employees
- 19
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Euronext - Paris
- Shares in Issue
- 7,758,724
- Address
- 60, LYON, 69008
- Web
- https://www.theranexus.com/
- Phone
- +33 188897031
- Auditors
- Ernst & Young et Autres
Upcoming Events for ALTHX
Q3 2024 Theranexus SA Cashflow Reports
Similar to ALTHX
Abionyx Pharma SA
Euronext - Paris
Abivax SA
Euronext - Paris
Acticor Biotech SA
Euronext - Paris
Adocia SA
Euronext - Paris
Biophytis SA
Euronext - Paris
FAQ
What is the Theranexus SA share price?
As of Today at 23:40 UTC, shares in Theranexus SA are trading at €0.63. This share price information is delayed by 15 minutes.
How has the Theranexus SA share price performed this year?
Shares in Theranexus SA last closed at €0.63 and the price had moved by -45.9% over the past 365 days. In terms of relative price strength the Theranexus SA share price has underperformed the FTSE Global All Cap Index by -51.47% over the past year.
What are the analyst and broker recommendations for Theranexus SA?
The overall consensus recommendation for Theranexus SA is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Theranexus SA dividend yield?
Theranexus SA does not currently pay a dividend.
Does Theranexus SA pay a dividend?
Theranexus SA does not currently pay a dividend.
When does Theranexus SA next pay dividends?
Theranexus SA does not currently pay a dividend.
How do I buy Theranexus SA shares?
To buy shares in Theranexus SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Theranexus SA?
As of the previous close price of €0.63, shares in Theranexus SA had a market capitalisation of €4.92m.
Where are Theranexus SA shares listed?
Here are the trading details for Theranexus SA:
- Country of listing: France
- Exchange: PAR
- Ticker Symbol: ALTHX
What kind of share is Theranexus SA?
Based on an overall assessment of its quality, value and momentum Theranexus SA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Theranexus SA share price forecast for 2024?
The analyst consensus target price for shares in Theranexus SA is €4.00. That is 530.91% above the last closing price of €0.63.
Analysts covering Theranexus SA currently have a consensus Earnings Per Share (EPS) forecast of -€1.01 for the next financial year.
Find out moreWhat is the trend in the Theranexus SA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Theranexus SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -42.43%.
As of the last closing price of €0.63, shares in Theranexus SA were trading -32.88% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Theranexus SA PE Ratio?
The Theranexus SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at €0.63.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Theranexus SA?
Theranexus SA's management team is headed by:
- Franck Mouthon - CHM
- Mathieu Charveriat - DCE
- Thierry Lambert - CFO
- Werner Rein - OTH
- Julien Veys - OTH
- Sebastien Descarpentries - DRC
- Rodolphe Besserve - IND
- Eric Doulat - IND
- Jerome Martinez - IND